Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
estradiol + progesterone (University of Illinois Chicago)
- Development stage
- Phase 4
- Lead developer
- University of Illinois Chicago
- Modality
- Small Molecules
- Administration
- Transdermal, Oral
01
Overview
This perimenstrual hormone stabilization intervention is an experimental combination therapy being developed by researchers at the University of Illinois at Chicago (UIC) to treat suicidal ideation in females. The treatment consists of a transdermal estradiol patch (0.1 mg/24 hrs) and oral micronized progesterone (200 mg/day) administered for two weeks starting seven days after ovulation. The mechanism of action involves stabilizing ovarian hormone levels to prevent the acute perimenstrual withdrawal of estradiol and progesterone, which has been linked to increased suicide risk, hopelessness, and hyperarousal in sensitive individuals. This approach is currently being evaluated in the CLEAR-3 (Hormone Stabilization for Proximal Suicide Risk) clinical trial to determine if preventing hormone drops can mitigate proximal suicide risk in reproductive-age females.
- Other names
- Perimenstrual hormone stabilization interventionHormone Stabilization for Proximal Suicide RiskCLEAR-3 interventionCLEAR3 interventionCLEAR 3 intervention
02
Targets
ESR1 (ERα)ESR2 (ERβ)GPER1 (G protein-coupled estrogen receptor 1)PR-A (Progesterone Receptor A)RB1 (Retinoblastoma-associated Protein)PR (Progesterone receptor)
Beyond the preview
Go deeper on estradiol + progesterone (University of Illinois Chicago).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on estradiol + progesterone (University of Illinois Chicago).